IMUC is really building multiple layers of protection of their technology. The main coverage comes from the previously issued patent on ICT-107 and its composition of the 6 antigens used to treat brain tumors. In addition, they own specific issued and pending patents on certain other antigens such as IL13Ra and CD133. If you factor in the existing patents they already have on the use of antigen loaded dendritic cells used in combination with chemo, it creates robust protection for their proprietary technology.
These are very strategic moves by IMUC management that really protect both the company and increase shareholder value in the long run. By layering manufacturing IP on top is creating additional protection around processes which are superior to DNDN.
There is no IP around the use of tumor lysates as it has been routinely done, this will leave NWBO with little protection if any since they use tumor lysates as antigen in their treatment. ICT-107 cannot be replicated or copied since that patent is very defined and specific on its composition.
Your information seems all well and good, but just because they have a specific patent on the treatment, does not mean they will be able to deliver it without other patents as was made evident by this article.
"The licensed technology underlies ICT-107"....that says to me that the process would not work without that piece of technology...is that accurate or not? This doesn't seem like a layered protection, but a fundamental part of the ICT-107 treatment that needs to be in place or the processes would not work or be as effective.